On October 31, 2021, Baggio, Diva; Tan, Sean; Porch, Kylie; Shortt, Jake; Ko, Brian published an article.Application of 380843-75-4 The title of the article was Prediction of cardiovascular events in patients with chronic myeloid leukaemia using baseline risk factors and coronary artery calcium scoring. And the article contained the following:
A standardised method for cardiovascular risk stratification in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors is lacking. We report an algorithm for risk stratification applicable to all patients commencing tyrosine kinase inhibitor therapy based on age, prior cardiovascular disease and Framingham Risk Score, incorporating coronary artery calcium scoring in patients at intermediate Framingham Risk Score risk. Of 88 patients retrospectively studied, major adverse cardiovascular event rates in our study-defined low-, intermediate- and high-risk categories were 0%, 10% and 19% resp. Of nine patients down-classified from intermediate to low risk on the basis of coronary artery calcium scoring, none went on to experience a major adverse cardiovascular event. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Application of 380843-75-4
The Article related to chronic myeloid leukemia coronary artery calcium algorithm bosutinib, calcium scoring, cardio-oncology, chronic myeloid leukaemia, coronary artery, tyrosine kinase inhibitor and other aspects.Application of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics